Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy
Identifieur interne : 000D49 ( Pmc/Corpus ); précédent : 000D48; suivant : 000D50Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy
Auteurs : Hisham Momattin ; Khurram Mohammed ; Alimuddin Zumla ; Ziad A. Memish ; Jaffar A. Al-TawfiqSource :
- International Journal of Infectious Diseases [ 1201-9712 ] ; 2013.
Abstract
The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.
Url:
DOI: 10.1016/j.ijid.2013.07.002
PubMed: 23993766
PubMed Central: 7110699
Links to Exploration step
PMC:7110699Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy</title><author><name sortKey="Momattin, Hisham" sort="Momattin, Hisham" uniqKey="Momattin H" first="Hisham" last="Momattin">Hisham Momattin</name><affiliation><nlm:aff id="aff0005">Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Mohammed, Khurram" sort="Mohammed, Khurram" uniqKey="Mohammed K" first="Khurram" last="Mohammed">Khurram Mohammed</name><affiliation><nlm:aff id="aff0005">Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:aff id="aff0010">Division of Infection and Immunity, University College London, London, and University College London Hospitals NHS Foundation Trust</nlm:aff></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name><affiliation><nlm:aff id="aff0015">Deputy Minister for Public Health, and Director WHO Collaborating Center for Mass Gathering Medicine Ministry of Health, and Professor, Al-Faisal University, Riyadh, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A." last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name><affiliation><nlm:aff id="aff0020">Specialty Internal Medicine, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia, and Indiana University School of Medicine, Indiana, USA</nlm:aff></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PMC</idno><idno type="pmid">23993766</idno><idno type="pmc">7110699</idno><idno type="url">http://www.ncbi.nlm.nih.gov/pmc/articles/PMC7110699</idno><idno type="RBID">PMC:7110699</idno><idno type="doi">10.1016/j.ijid.2013.07.002</idno><date when="2013">2013</date><idno type="wicri:Area/Pmc/Corpus">000D49</idno><idno type="wicri:explorRef" wicri:stream="Pmc" wicri:step="Corpus" wicri:corpus="PMC">000D49</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en" level="a" type="main">Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy</title><author><name sortKey="Momattin, Hisham" sort="Momattin, Hisham" uniqKey="Momattin H" first="Hisham" last="Momattin">Hisham Momattin</name><affiliation><nlm:aff id="aff0005">Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Mohammed, Khurram" sort="Mohammed, Khurram" uniqKey="Mohammed K" first="Khurram" last="Mohammed">Khurram Mohammed</name><affiliation><nlm:aff id="aff0005">Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Zumla, Alimuddin" sort="Zumla, Alimuddin" uniqKey="Zumla A" first="Alimuddin" last="Zumla">Alimuddin Zumla</name><affiliation><nlm:aff id="aff0010">Division of Infection and Immunity, University College London, London, and University College London Hospitals NHS Foundation Trust</nlm:aff></affiliation></author><author><name sortKey="Memish, Ziad A" sort="Memish, Ziad A" uniqKey="Memish Z" first="Ziad A." last="Memish">Ziad A. Memish</name><affiliation><nlm:aff id="aff0015">Deputy Minister for Public Health, and Director WHO Collaborating Center for Mass Gathering Medicine Ministry of Health, and Professor, Al-Faisal University, Riyadh, Saudi Arabia</nlm:aff></affiliation></author><author><name sortKey="Al Tawfiq, Jaffar A" sort="Al Tawfiq, Jaffar A" uniqKey="Al Tawfiq J" first="Jaffar A." last="Al-Tawfiq">Jaffar A. Al-Tawfiq</name><affiliation><nlm:aff id="aff0020">Specialty Internal Medicine, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia, and Indiana University School of Medicine, Indiana, USA</nlm:aff></affiliation></author></analytic><series><title level="j">International Journal of Infectious Diseases</title><idno type="ISSN">1201-9712</idno><idno type="eISSN">1878-3511</idno><imprint><date when="2013">2013</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en"><p>The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.</p></div></front><back><div1 type="bibliography"><listBibl><biblStruct><analytic><author><name sortKey="Albarrak, A M" uniqKey="Albarrak A">A.M. AlBarrak</name></author><author><name sortKey="Stephens, G M" uniqKey="Stephens G">G.M. Stephens</name></author><author><name sortKey="Hewson, R" uniqKey="Hewson R">R. Hewson</name></author><author><name sortKey="Memish, Z A" uniqKey="Memish Z">Z.A. Memish</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Assiri, A" uniqKey="Assiri A">A. Assiri</name></author><author><name sortKey="Mcgeer, A" uniqKey="Mcgeer A">A. McGeer</name></author><author><name sortKey="Perl, T M" uniqKey="Perl T">T.M. Perl</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Assiri, A" uniqKey="Assiri A">A. Assiri</name></author><author><name sortKey="Al Tawfi Q, J A" uniqKey="Al Tawfi Q J">J.A. Al-Tawfi q</name></author><author><name sortKey="Al Rabeeah, A A" uniqKey="Al Rabeeah A">A.A. Al-Rabeeah</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Stockman, L J" uniqKey="Stockman L">L.J. Stockman</name></author><author><name sortKey="Bellamy, R" uniqKey="Bellamy R">R. Bellamy</name></author><author><name sortKey="Garner, P" uniqKey="Garner P">P. Garner</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Poutanen, S M" uniqKey="Poutanen S">S.M. Poutanen</name></author><author><name sortKey="Low, D E" uniqKey="Low D">D.E. Low</name></author><author><name sortKey="Henry, B" uniqKey="Henry B">B. Henry</name></author><author><name sortKey="Finkelstein, S" uniqKey="Finkelstein S">S. Finkelstein</name></author><author><name sortKey="Rose, D" uniqKey="Rose D">D. Rose</name></author><author><name sortKey="Green, K" uniqKey="Green K">K. Green</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Tsang, K W" uniqKey="Tsang K">K.W. Tsang</name></author><author><name sortKey="Ho, P L" uniqKey="Ho P">P.L. Ho</name></author><author><name sortKey="Ooi, G C" uniqKey="Ooi G">G.C. Ooi</name></author><author><name sortKey="Yee, W K" uniqKey="Yee W">W.K. Yee</name></author><author><name sortKey="Wang, T" uniqKey="Wang T">T. Wang</name></author><author><name sortKey="Chan Yeung, M" uniqKey="Chan Yeung M">M. Chan-Yeung</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Booth, C M" uniqKey="Booth C">C.M. Booth</name></author><author><name sortKey="Matukas, L M" uniqKey="Matukas L">L.M. Matukas</name></author><author><name sortKey="Tomlinson, G A" uniqKey="Tomlinson G">G.A. Tomlinson</name></author><author><name sortKey="Rachlis, A R" uniqKey="Rachlis A">A.R. Rachlis</name></author><author><name sortKey="Rose, D B" uniqKey="Rose D">D.B. Rose</name></author><author><name sortKey="Dwosh, H A" uniqKey="Dwosh H">H.A. Dwosh</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Hsu, L Y" uniqKey="Hsu L">L.Y. Hsu</name></author><author><name sortKey="Lee, C C" uniqKey="Lee C">C.C. Lee</name></author><author><name sortKey="Green, J A" uniqKey="Green J">J.A. Green</name></author><author><name sortKey="Ang, B" uniqKey="Ang B">B. Ang</name></author><author><name sortKey="Paton, N I" uniqKey="Paton N">N.I. Paton</name></author><author><name sortKey="Lee, L" uniqKey="Lee L">L. Lee</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Peiris, J S" uniqKey="Peiris J">J.S. Peiris</name></author><author><name sortKey="Chu, C M" uniqKey="Chu C">C.M. Chu</name></author><author><name sortKey="Cheng, V C" uniqKey="Cheng V">V.C. Cheng</name></author><author><name sortKey="Chan, K S" uniqKey="Chan K">K.S. Chan</name></author><author><name sortKey="Hung, I F" uniqKey="Hung I">I.F. Hung</name></author><author><name sortKey="Poon, L L" uniqKey="Poon L">L.L. Poon</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Zhao, Z" uniqKey="Zhao Z">Z. Zhao</name></author><author><name sortKey="Zhang, F" uniqKey="Zhang F">F. Zhang</name></author><author><name sortKey="Xu, M" uniqKey="Xu M">M. Xu</name></author><author><name sortKey="Huang, K" uniqKey="Huang K">K. Huang</name></author><author><name sortKey="Zhong, W" uniqKey="Zhong W">W. Zhong</name></author><author><name sortKey="Cai, W" uniqKey="Cai W">W. Cai</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Sung, J J" uniqKey="Sung J">J.J. Sung</name></author><author><name sortKey="Wu, A" uniqKey="Wu A">A. Wu</name></author><author><name sortKey="Joynt, G M" uniqKey="Joynt G">G.M. Joynt</name></author><author><name sortKey="Yuen, K Y" uniqKey="Yuen K">K.Y. Yuen</name></author><author><name sortKey="Lee, N" uniqKey="Lee N">N. Lee</name></author><author><name sortKey="Chan, P K" uniqKey="Chan P">P.K. Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Ooi, C G" uniqKey="Ooi C">C.G. Ooi</name></author><author><name sortKey="Khong, P L" uniqKey="Khong P">P.L. Khong</name></author><author><name sortKey="Ho, J C" uniqKey="Ho J">J.C. Ho</name></author><author><name sortKey="Lam, B" uniqKey="Lam B">B. Lam</name></author><author><name sortKey="Wong, W M" uniqKey="Wong W">W.M. Wong</name></author><author><name sortKey="Yiu, W C" uniqKey="Yiu W">W.C. Yiu</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Leong, H N" uniqKey="Leong H">H.N. Leong</name></author><author><name sortKey="Ang, B" uniqKey="Ang B">B. Ang</name></author><author><name sortKey="Earnest, A" uniqKey="Earnest A">A. Earnest</name></author><author><name sortKey="Teoh, C" uniqKey="Teoh C">C. Teoh</name></author><author><name sortKey="Xu, W" uniqKey="Xu W">W. Xu</name></author><author><name sortKey="Leo, Y S" uniqKey="Leo Y">Y.S. Leo</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, K S" uniqKey="Chan K">K.S. Chan</name></author><author><name sortKey="Lai, S T" uniqKey="Lai S">S.T. Lai</name></author><author><name sortKey="Chu, C M" uniqKey="Chu C">C.M. Chu</name></author><author><name sortKey="Tsui, E" uniqKey="Tsui E">E. Tsui</name></author><author><name sortKey="Tam, C Y" uniqKey="Tam C">C.Y. Tam</name></author><author><name sortKey="Wong, M M" uniqKey="Wong M">M.M. Wong</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chu, C M" uniqKey="Chu C">C.M. Chu</name></author><author><name sortKey="Cheng, V C" uniqKey="Cheng V">V.C. Cheng</name></author><author><name sortKey="Hung, I F" uniqKey="Hung I">I.F. Hung</name></author><author><name sortKey="Wong, M M" uniqKey="Wong M">M.M. Wong</name></author><author><name sortKey="Chan, K H" uniqKey="Chan K">K.H. Chan</name></author><author><name sortKey="Chan, K S" uniqKey="Chan K">K.S. Chan</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Yeh, K M" uniqKey="Yeh K">K.M. Yeh</name></author><author><name sortKey="Chiueh, T S" uniqKey="Chiueh T">T.S. Chiueh</name></author><author><name sortKey="Siu, L K" uniqKey="Siu L">L.K. Siu</name></author><author><name sortKey="Lin, J C" uniqKey="Lin J">J.C. Lin</name></author><author><name sortKey="Chan, P K" uniqKey="Chan P">P.K. Chan</name></author><author><name sortKey="Peng, M Y" uniqKey="Peng M">M.Y. Peng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Burnouf, T" uniqKey="Burnouf T">T. Burnouf</name></author><author><name sortKey="Radosevich, M" uniqKey="Radosevich M">M. Radosevich</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Cheng, Y" uniqKey="Cheng Y">Y. Cheng</name></author><author><name sortKey="Wong, R" uniqKey="Wong R">R. Wong</name></author><author><name sortKey="Soo, Y O" uniqKey="Soo Y">Y.O. Soo</name></author><author><name sortKey="Wong, W S" uniqKey="Wong W">W.S. Wong</name></author><author><name sortKey="Lee, C K" uniqKey="Lee C">C.K. Lee</name></author><author><name sortKey="Ng, M H" uniqKey="Ng M">M.H. Ng</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Soo, Y O" uniqKey="Soo Y">Y.O. Soo</name></author><author><name sortKey="Cheng, Y" uniqKey="Cheng Y">Y. Cheng</name></author><author><name sortKey="Wong, R" uniqKey="Wong R">R. Wong</name></author><author><name sortKey="Hui, D S" uniqKey="Hui D">D.S. Hui</name></author><author><name sortKey="Lee, C K" uniqKey="Lee C">C.K. Lee</name></author><author><name sortKey="Tsang, K K" uniqKey="Tsang K">K.K. Tsang</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Loutfy, M R" uniqKey="Loutfy M">M.R. Loutfy</name></author><author><name sortKey="Blatt, L M" uniqKey="Blatt L">L.M. Blatt</name></author><author><name sortKey="Siminovitch, K A" uniqKey="Siminovitch K">K.A. Siminovitch</name></author><author><name sortKey="Ward, S" uniqKey="Ward S">S. Ward</name></author><author><name sortKey="Wolff, B" uniqKey="Wolff B">B. Wolff</name></author><author><name sortKey="Lho, H" uniqKey="Lho H">H. Lho</name></author></analytic></biblStruct><biblStruct><analytic><author><name sortKey="Chan, K H" uniqKey="Chan K">K.H. Chan</name></author><author><name sortKey="Chan, J F" uniqKey="Chan J">J.F. Chan</name></author><author><name sortKey="Tse, H" uniqKey="Tse H">H. Tse</name></author><author><name sortKey="Chen, H" uniqKey="Chen H">H. Chen</name></author><author><name sortKey="Lau, C C" uniqKey="Lau C">C.C. Lau</name></author><author><name sortKey="Cai, J P" uniqKey="Cai J">J.P. Cai</name></author></analytic></biblStruct><biblStruct></biblStruct><biblStruct><analytic><author><name sortKey="Raj, V S" uniqKey="Raj V">V.S. Raj</name></author><author><name sortKey="Mou, H" uniqKey="Mou H">H. Mou</name></author></analytic></biblStruct></listBibl></div1></back></TEI><pmc article-type="research-article"><pmc-dir>properties open_access</pmc-dir>
<front><journal-meta><journal-id journal-id-type="nlm-ta">Int J Infect Dis</journal-id><journal-id journal-id-type="iso-abbrev">Int. J. Infect. Dis</journal-id><journal-title-group><journal-title>International Journal of Infectious Diseases</journal-title></journal-title-group><issn pub-type="ppub">1201-9712</issn><issn pub-type="epub">1878-3511</issn><publisher><publisher-name>International Society for Infectious Diseases. Published by Elsevier Ltd.</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">23993766</article-id><article-id pub-id-type="pmc">7110699</article-id><article-id pub-id-type="publisher-id">S1201-9712(13)00229-4</article-id><article-id pub-id-type="doi">10.1016/j.ijid.2013.07.002</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy</article-title></title-group><contrib-group><contrib contrib-type="author" id="aut0005"><name><surname>Momattin</surname><given-names>Hisham</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0010"><name><surname>Mohammed</surname><given-names>Khurram</given-names></name><xref rid="aff0005" ref-type="aff">a</xref></contrib><contrib contrib-type="author" id="aut0015"><name><surname>Zumla</surname><given-names>Alimuddin</given-names></name><xref rid="aff0010" ref-type="aff">b</xref></contrib><contrib contrib-type="author" id="aut0020"><name><surname>Memish</surname><given-names>Ziad A.</given-names></name><xref rid="aff0015" ref-type="aff">c</xref></contrib><contrib contrib-type="author" id="aut0025"><name><surname>Al-Tawfiq</surname><given-names>Jaffar A.</given-names></name><email>jaffar.tawfiq@aramco.com</email><email>jaltawfi@yahoo.com</email><xref rid="aff0020" ref-type="aff">d</xref><xref rid="cor0005" ref-type="corresp">⁎</xref></contrib></contrib-group><aff id="aff0005"><label>a</label>Pharmacy Services Division, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia</aff><aff id="aff0010"><label>b</label>Division of Infection and Immunity, University College London, London, and University College London Hospitals NHS Foundation Trust</aff><aff id="aff0015"><label>c</label>Deputy Minister for Public Health, and Director WHO Collaborating Center for Mass Gathering Medicine Ministry of Health, and Professor, Al-Faisal University, Riyadh, Saudi Arabia</aff><aff id="aff0020"><label>d</label>Specialty Internal Medicine, Saudi Aramco Medical Services Organization, Dhahran, Saudi Arabia, and Indiana University School of Medicine, Indiana, USA</aff><author-notes><corresp id="cor0005"><label>⁎</label>Corresponding author. P.O. Box 76, Room A-428-2, Building 61, Dhahran Health Center, Saudi Aramco, Dhahran 31311, Saudi Arabia. Tel.: +966 3 877 3524; fax: +966 3 877 3790. <email>jaffar.tawfiq@aramco.com</email><email>jaltawfi@yahoo.com</email></corresp></author-notes><pub-date pub-type="pmc-release"><day>29</day><month>8</month><year>2013</year></pub-date><pmc-comment> PMC Release delay is 0 months and 0 days and was based on .</pmc-comment>
<pub-date pub-type="ppub"><month>10</month><year>2013</year></pub-date><pub-date pub-type="epub"><day>29</day><month>8</month><year>2013</year></pub-date><volume>17</volume><issue>10</issue><fpage>e792</fpage><lpage>e798</lpage><permissions><copyright-statement>Copyright © 2013 International Society for Infectious Diseases. Published by Elsevier Ltd.</copyright-statement><copyright-year>2013</copyright-year><copyright-holder>International Society for Infectious Diseases</copyright-holder><license><license-p>Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.</license-p></license></permissions><abstract id="abs0005"><p>The Middle East Respiratory Syndrome coronavirus (MERS-CoV) has been detected in a number of countries in the Middle East and Europe with an apparently high mortality rate. It is phylogenetically related to the SARS coronavirus and has also been associated with severe respiratory illness as well as nosocomial transmission in healthcare settings. Current international recommendations do not support any specific therapies; however, there are a number of agents, which were used during the SARS epidemic of 2003. It is possible that these might be active against the related MERS coronavirus. We have reviewed the literature on the safety and efficacy of therapies used in patients with SARS with a view to their potential use in patients with MERS-CoV infections.</p></abstract><kwd-group id="kwd0005"><title>Keywords</title><kwd>MERS-CoV</kwd><kwd>Interferon</kwd><kwd>Ribavarin</kwd><kwd>SARS</kwd></kwd-group></article-meta><notes><p id="misc0005"><bold>Corresponding Editor:</bold> Eskild Petersen, MD, DMSc, MBA, Editor-in-Chief, International Journal of Infectious Diseases</p></notes></front><body><sec id="sec0005"><label>1</label><title>Introduction</title><p id="par0005">Coronaviruses are RNA viruses which usually cause mild upper respiratory illnesses. The emergence of SARS (severe acute respiratory Syndrome) MERS (Middle east respiratory syndrome) has focussed global attention on the clinical significance of cornaviruses.</p><p id="par0010">The current Middle East Respiratory Syndrome Novel coronavirus (MERS-CoV) was first isolated in June 2012 from the respiratory tract of a businessman in the Bisha area of Saudi Arabia, who subsequently died of pneumonia and renal failure.<xref rid="bib0005" ref-type="bibr"><sup>1</sup></xref> As of 28 July 2013 MERS-CoV has caused 91 laboratory confirmed cases and 46 deaths, representing a high case fatality rate of 50%.<xref rid="bib0010" ref-type="bibr"><sup>2</sup></xref> The high case fatality rate is likely related to the pattern of the disease as we probably are seeing only the tip of the iceberg of critically ill and admitted patients. The high fatality rate is likely to decline as milder clinical cases emerge. Similar to SARS, common symptoms in patients with MERS-CoV include fever, cough, shortness of breath, and gastrointestinal symptoms. Most patients have had pneumonia and the majority was reported to have multiple co-morbid conditions.<xref rid="bib0015" ref-type="bibr">3</xref>, <xref rid="bib0020" ref-type="bibr">4</xref></p><p id="par0015">The rapid deployment of effective therapeutics is a high priority as there is currently no specific therapy or vaccine for MERS-CoV. The clinical experience from SARS suggests that a number of interventions including ribavirin with and without corticosteroids, interferon alfa with corticosteroids, ribavirin with lopinavir and ritonavir, and convalescent plasma may improve the outcome in patients but the data are not conclusive.<xref rid="bib0025" ref-type="bibr"><sup>5</sup></xref></p><p id="par0020">The purpose of this review is first to summarize the effectiveness of these treatments, in an attempt to identify a therapeutic approach that could help select the most appropriate therapeutic options for patients with MERS-CoV infections.</p></sec><sec id="sec0010"><label>2</label><title>Methods</title><p id="par0025">We systematically searched the literature databases (PubMed, Science Direct and the Cochrane database) for published studies. We used the key words “SARS”, “coronavirus”, in combination with “treatment”, human studies, randomized controlled trials (RCT), prospective <italic>or</italic> retrospective cohort designs, case-control designs, <italic>or</italic> case series; agents included were ribavirin, interferon, Lopinavir and ritonavir (LPV/r), and convalescent plasma. We exclude corticosteroid studies as this was beyond the scope of this review and the management of severe pneumonia has been well covered in the WHO guideline.<xref rid="bib0030" ref-type="bibr"><sup>6</sup></xref></p><p id="par0030">Data extracted from these publications include: authors name, publication year, type of study, level of evidence, sample size, interventions dose, duration, indication, route, and time of administration, number of patients, and efficacy and safety outcome of these interventions. The outcomes of interest included mortality rate, measures of morbidity and adverse effects. The outcomes reported in the selected studies included death, mechanical ventilation, improvement of symptoms, admission to the intensive care unit, infectious complications, successful discharge and adverse effects.</p></sec><sec id="sec0015"><label>3</label><title>Assessment of study quality</title><p id="par0035">The clinical studies were all critically appraised. Aspects that were assessed included study design, the possibility of bias in the selection of the control group and treatment allocation, and whether the treatment regimen and reporting of outcomes were consistent. The studies were tabulated and summarized in a narrative way, and were grouped by the treatment strategy. We categorized each article depending on which drug was used. We tabulated results as type of study, dose, duration, time of administration, and indication of medication, number of patients included in that study, plus the final outcomes.</p><p id="par0040">The studies were scored using the US Preventive Services Task Force scoring system<xref rid="bib0035" ref-type="bibr"><sup>7</sup></xref>, where Level of Evidence.<list list-type="simple" id="lis0005"><list-item id="lsti0005"><p id="par0045">LOE, I: Evidence obtained from at least one properly designed randomized controlled trial.</p></list-item><list-item id="lsti0025"><p id="par0140">Level II-1: Evidence obtained from well-designed controlled trials without randomization.</p></list-item><list-item id="lsti0010"><p id="par0050">Level II-2: Evidence obtained from well-designed cohort or case-control analytic studies, preferably from more than one center or research group.</p></list-item><list-item id="lsti0015"><p id="par0055">Level II-3: Evidence obtained from multiple time series with or without the intervention. Dramatic results in uncontrolled trials might also be regarded as this type of evidence.</p></list-item><list-item id="lsti0020"><p id="par0060">Level III: Opinions of respected authorities, based on clinical experience, descriptive studies, or reports of expert committees.</p></list-item></list></p></sec><sec id="sec0020"><label>4</label><title>Results</title><p id="par0065">We identified 54 studies about SARS or coronavirus and we included 19 studies only. We excluded 35 studies since 14 of them were in vitro studies, 15 corticosteroid studies, and 6 were non-therapeutic studies. Overall, we analyzed 19 studies, nine used ribavirin alone or with interferon (<xref rid="tbl0005" ref-type="table">Table 1</xref>)<xref rid="bib0040" ref-type="bibr">8</xref>, <xref rid="bib0045" ref-type="bibr">9</xref>, <xref rid="bib0050" ref-type="bibr">10</xref>, <xref rid="bib0055" ref-type="bibr">11</xref>, <xref rid="bib0060" ref-type="bibr">12</xref>, <xref rid="bib0065" ref-type="bibr">13</xref>, <xref rid="bib0070" ref-type="bibr">14</xref>, <xref rid="bib0075" ref-type="bibr">15</xref>, <xref rid="bib0080" ref-type="bibr">16</xref>, two used lopinavir and ritonavir (<xref rid="tbl0010" ref-type="table">Table 2</xref>)<xref rid="bib0085" ref-type="bibr">17</xref>, <xref rid="bib0090" ref-type="bibr">18</xref>, six used convalescent plasma (<xref rid="tbl0015" ref-type="table">Table 3</xref>)<xref rid="bib0095" ref-type="bibr">19</xref>, <xref rid="bib0100" ref-type="bibr">20</xref>, <xref rid="bib0105" ref-type="bibr">21</xref>, <xref rid="bib0110" ref-type="bibr">22</xref>, there was one study of Interferon alpha (<xref rid="tbl0020" ref-type="table">Table 4</xref>)<xref rid="bib0115" ref-type="bibr"><sup>23</sup></xref> and one study comparing Interferon alpha versus ribavirin<xref rid="bib0065" ref-type="bibr"><sup>13</sup></xref>. Summaries of the different studies are presented in <xref rid="tbl0005" ref-type="table">Table 1</xref>, <xref rid="tbl0010" ref-type="table">Table 2</xref>, <xref rid="tbl0015" ref-type="table">Table 3</xref>, <xref rid="tbl0020" ref-type="table">Table 4</xref>.<table-wrap position="float" id="tbl0005"><label>Table 1</label><caption><p>Summary of Ribavarin Therapy in the treatment of SARS patients</p></caption><table frame="hsides" rules="groups"><tbody><tr><td align="left"><inline-graphic xlink:href="fx1a_lrg.gif"></inline-graphic></td></tr><tr><td align="left"><inline-graphic xlink:href="fx1b_lrg.gif"></inline-graphic></td></tr></tbody></table></table-wrap><table-wrap position="float" id="tbl0010"><label>Table 2</label><caption><p>Lopinavir/Ritonavir studies</p></caption><graphic xlink:href="fx2_lrg"></graphic></table-wrap><table-wrap position="float" id="tbl0015"><label>Table 3</label><caption><p>Convalescent Plasma studies</p></caption><graphic xlink:href="fx3_lrg"></graphic></table-wrap><table-wrap position="float" id="tbl0020"><label>Table 4</label><caption><p>Interferon alpha studies</p></caption><graphic xlink:href="fx4_lrg"></graphic></table-wrap></p></sec><sec id="sec0025"><label>5</label><title>Discussion</title><p id="par0070">There has been a lot of concern worldwide about the emergence of the MERS-CoV. Although infection control, molecular diagnostics and international public health have improved considerably since the 2003 SARS epidemic, there are still no proven or licensed therapies for any coronavirus infection. The high mortality associated with MERS-CoV led us to conduct this systematic review to summarize the available options for treatment for novel coronavirus infection based on previous reports of therapy of SARS, a related coronavirus.</p><p id="par0075">The most commonly used agent was the broad spectrum antiviral ribavirin. There were seven reports of the use of ribavirin in SARS patients although only four reported control groups. The mortality benefit was inconsistent with mortality rates of between 5% and 42.8%,<xref rid="bib0040" ref-type="bibr">8</xref>, <xref rid="bib0045" ref-type="bibr">9</xref>, <xref rid="bib0050" ref-type="bibr">10</xref>, <xref rid="bib0055" ref-type="bibr">11</xref>, <xref rid="bib0060" ref-type="bibr">12</xref>, <xref rid="bib0065" ref-type="bibr">13</xref>, <xref rid="bib0070" ref-type="bibr">14</xref> two studies showed improvements of symptoms in 71.4%-80% of patients, and ICU admission rates of 13%-20%.<xref rid="bib0040" ref-type="bibr">8</xref>, <xref rid="bib0045" ref-type="bibr">9</xref> The major problem with ribavirin was the significant incidence of adverse events especially hemolysis which was reported in 68.5%.<xref rid="bib0050" ref-type="bibr"><sup>10</sup></xref></p><p id="par0080">The timing of the start of antiviral agents is important in most virus infections. One study compared oseltamivir versus ribavirin and showed no obvious response to ribavirin, however, the treatment were started after 10-14 days of symptoms which might have led to the poorer outcomes.<xref rid="bib0055" ref-type="bibr"><sup>11</sup></xref></p><p id="par0085">There was only one randomized controlled trial: this compared ribavirin versus interferon-1α and showed no advantage of ribavirin over interferon in patients with SARS.<xref rid="bib0065" ref-type="bibr"><sup>13</sup></xref> In addition, there were observational studies comparing Interferon-1α with untreated controls.<xref rid="bib0115" ref-type="bibr"><sup>23</sup></xref> Interferon led to improvements in clinical and laboratory parameters compared with control patients.<xref rid="bib0115" ref-type="bibr"><sup>23</sup></xref> However, there was no standard regime used and adverse events were not well documented.</p><p id="par0090">The addition of lopinavir/ritonavir to ribavirin regimen was associated with improved clinical outcome and reduces the death rate comparing to ribavirin regimen alone in observational studies.<xref rid="bib0085" ref-type="bibr">17</xref>, <xref rid="bib0090" ref-type="bibr">18</xref> These studies are detailed in <xref rid="tbl0010" ref-type="table">Table 2</xref>.</p><p id="par0095">Few studies addressed the effect of convalescent plasma.<xref rid="bib0095" ref-type="bibr">19</xref>, <xref rid="bib0100" ref-type="bibr">20</xref>, <xref rid="bib0105" ref-type="bibr">21</xref>, <xref rid="bib0110" ref-type="bibr">22</xref> These studies were mainly case reports which limit the generalizability of their findings. In three studies of SARS patients, patients in the plasma group had a shorter hospital stay (58.3% -73.4% versus 15.6%- 19%; P < 0.001)<xref rid="bib0105" ref-type="bibr">21</xref>, <xref rid="bib0110" ref-type="bibr">22</xref> and lower mortality than the comparator group (0%- 12.5% versus 17% 23.8%).<xref rid="bib0095" ref-type="bibr">19</xref>, <xref rid="bib0105" ref-type="bibr">21</xref>, <xref rid="bib0110" ref-type="bibr">22</xref></p><p id="par0100">Intriguingly, an in vitro study showed that convalescent plasma from SARS patients might contain cross-reactive antibodies against other beta-coronavirus including MERS-CoV.<xref rid="bib0120" ref-type="bibr"><sup>24</sup></xref> Of 28 sera, 7 (25%) had antibodies anti-MERS-CoV neutralizing antibodies at low titers.<xref rid="bib0120" ref-type="bibr"><sup>24</sup></xref> Convalescent sera was recommended in a recent study by the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC).<xref rid="bib0125" ref-type="bibr"><sup>25</sup></xref> Cross- reactive antibodies may be present in convalescent plasma from SARS patients against other beta-coronavirus and may be associated with a better outcome, reduced mortality, and shorter hospital stay.<xref rid="bib0095" ref-type="bibr">19</xref>, <xref rid="bib0100" ref-type="bibr">20</xref>, <xref rid="bib0105" ref-type="bibr">21</xref>, <xref rid="bib0110" ref-type="bibr">22</xref> There are considerable technical hurdles to overcome before convalescent sera can be widely recommended as a therapeutic agent in the modern era. Currently, there is a need to establish a serology test to diagnose patients with mild disease and thus identify those patients as possible donors of convalescent sera.</p><p id="par0105">We conclude that the use of ribavirin may improve the outcome and reduce mortality as shown in a number of studies. One of the reasons for the failure of ribavirin in some reports may have been the timing for the use of ribavirin, after 6-14 days of symptom,<xref rid="bib0055" ref-type="bibr">11</xref>, <xref rid="bib0070" ref-type="bibr">14</xref>, <xref rid="bib0080" ref-type="bibr">16</xref> compared to studies which showed benefits when ribavirin was started within 48 hours of hospitalization or after diagnosis of SARS was established.<xref rid="bib0040" ref-type="bibr">8</xref>, <xref rid="bib0045" ref-type="bibr">9</xref>, <xref rid="bib0060" ref-type="bibr">12</xref>, <xref rid="bib0065" ref-type="bibr">13</xref>The major limitation of Ribavarin is its significant toxicity at the doses used to treat patients with SARS. Although the addition of lopinavir/ritonavir to ribavirin appeared to have a better outcome in patients with SARS.<xref rid="bib0085" ref-type="bibr">17</xref>, <xref rid="bib0090" ref-type="bibr">18</xref> There are reports that lopinavir/ritonavir is not active in vitro against the MERS-CoV.<xref rid="bib0125" ref-type="bibr"><sup>25</sup></xref> Other in vitro studies have failed to yield potent therapeutic agents despite a search including DPP4 inhibitors.<xref rid="bib0130" ref-type="bibr"><sup>26</sup></xref></p><p id="par0110">Among the limitations of this review are the heterogeneity of the reviewed studies in terms of the wide range of treatment dosages, frequency, and route of administration, duration, and timing of administration. The reported treatment effects should be interpreted with caution due to the lack of randomized, controlled trials.</p><p id="par0115">Also, while we have drawn on the SARS literature, and SARS is a closely related virus, there are clearly differences between SARS and the MERS-CoV and the data might not be able to be directly extrapolated to MERS-CoV infected patients. The use of the discussed agents would require monitoring hematological and biochemical parameters during treatment to detect and prevent adverse effects associated with therapy. Possible dosages of discussed agents especially with unavailability of intravenous ribavarin are listed in <xref rid="tbl0025" ref-type="table">Table 5</xref>. The table also includes the possible dosage of pegelated interferon-α (PegIFN—α) that is commonly used in the treatment of hepatitis C virus infection. PegIFN-α was 50-100 times more effective <italic>in vitro</italic> for MERS-CoV than SARS-CoV.<xref rid="bib0125" ref-type="bibr"><sup>25</sup></xref> The long half-life of PegIFN-α and the associated adverse effects calls for extra attention for the use of shorter-acting interferon.<xref rid="bib0125" ref-type="bibr"><sup>25</sup></xref> The use of interferon therapy with ribavirin is not recommended in patients with hepatitis C virus infection and renal dysfunction (Clcr <50 mL/minute).<table-wrap position="float" id="tbl0025"><label>Table 5</label><caption><p>Possible dosages and schedule of therapeutic agents for MERS-CoV Infection</p></caption><graphic xlink:href="fx5_lrg"></graphic></table-wrap></p><p id="par0120">With the emergence of MERS-CoV and the lack of high quality clinical evidence to support recommendations for the use of available therapeutic options, there is a clear need for developing protocols to be used in randomized-controlled trials in order to determine the most effective therapies for this novel emerging pathogen.</p></sec></body><back><ref-list id="bibl0005"><title>References</title><ref id="bib0005"><label>1</label><element-citation publication-type="journal" id="sbref0005"><person-group person-group-type="author"><name><surname>AlBarrak</surname><given-names>A.M.</given-names></name><name><surname>Stephens</surname><given-names>G.M.</given-names></name><name><surname>Hewson</surname><given-names>R.</given-names></name><name><surname>Memish</surname><given-names>Z.A.</given-names></name></person-group><article-title>Recovery from severe novel coronavirus infection</article-title><source>Saudi Med J</source><volume>33</volume><year>2012</year><fpage>1265</fpage><lpage>1269</lpage><pub-id pub-id-type="pmid">23232672</pub-id></element-citation></ref><ref id="bib0010"><label>2</label><mixed-citation publication-type="other" id="oref0010">CDC. Middle East Respiratory Syndrome. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.cdc.gov/coronavirus/mers/faq.html" id="intr0005">http://www.cdc.gov/coronavirus/mers/faq.html</ext-link> last accessed July 27, 2013.</mixed-citation></ref><ref id="bib0015"><label>3</label><element-citation publication-type="journal" id="sbref0015"><person-group person-group-type="author"><name><surname>Assiri</surname><given-names>A.</given-names></name><name><surname>McGeer</surname><given-names>A.</given-names></name><name><surname>Perl</surname><given-names>T.M.</given-names></name></person-group><article-title>Hospital outbreak of Middle East respiratory syndrome coronavirus</article-title><source>N Engl J Med</source><volume>369</volume><issue>5</issue><year>2013</year><fpage>407</fpage><lpage>416</lpage><pub-id pub-id-type="pmid">23782161</pub-id></element-citation></ref><ref id="bib0020"><label>4</label><element-citation publication-type="journal" id="sbref0020"><person-group person-group-type="author"><name><surname>Assiri</surname><given-names>A.</given-names></name><name><surname>Al-Tawfi q</surname><given-names>J.A.</given-names></name><name><surname>Al-Rabeeah</surname><given-names>A.A.</given-names></name></person-group><article-title>Epidemiological, demographic, and clinical characteristics of 47 cases of Middle East respiratory syndrome coronavirus disease from Saudi Arabia: a descriptive study</article-title><source>Lancet Infect Dis</source><year>2013</year><comment>published online July 26. <ext-link ext-link-type="doi" xlink:href="10.1016/S1473-3099(13)70204-4" id="intr0010">http://dx.doi.org/10.1016/S1473-3099(13)70204-4</ext-link></comment></element-citation></ref><ref id="bib0025"><label>5</label><element-citation publication-type="journal" id="sbref0025"><person-group person-group-type="author"><name><surname>Stockman</surname><given-names>L.J.</given-names></name><name><surname>Bellamy</surname><given-names>R.</given-names></name><name><surname>Garner</surname><given-names>P.</given-names></name></person-group><article-title>SARS: systematic review of treatment effects</article-title><source>PLoS Med.</source><volume>3</volume><year>2006</year><fpage>e343</fpage><pub-id pub-id-type="pmid">16968120</pub-id></element-citation></ref><ref id="bib0030"><label>6</label><mixed-citation publication-type="other" id="oref0030">World Health Organization. Clinical management of severe acute respiratory infections when novel coronavirus is suspected: What to do and what not to do. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf" id="intr0015">http://www.who.int/csr/disease/coronavirus_infections/InterimGuidance_ClinicalManagement_NovelCoronavirus_11Feb13u.pdf</ext-link></mixed-citation></ref><ref id="bib0035"><label>7</label><mixed-citation publication-type="other" id="oref0035">U.S. Preventive Services Task Force (August 1989). Guide to clinical preventive services: report of the U.S. Preventive Services Task Force. DIANE Publishing. pp. 24–. ISBN 978-1-56806-297-6.</mixed-citation></ref><ref id="bib0040"><label>8</label><element-citation publication-type="journal" id="sbref0040"><person-group person-group-type="author"><name><surname>Poutanen</surname><given-names>S.M.</given-names></name><name><surname>Low</surname><given-names>D.E.</given-names></name><name><surname>Henry</surname><given-names>B.</given-names></name><name><surname>Finkelstein</surname><given-names>S.</given-names></name><name><surname>Rose</surname><given-names>D.</given-names></name><name><surname>Green</surname><given-names>K.</given-names></name></person-group><article-title>Identification of severe acute respiratory Syndrome in Canada</article-title><source>N Eng J Med.</source><volume>348</volume><year>2003</year><fpage>1995</fpage><lpage>2005</lpage></element-citation></ref><ref id="bib0045"><label>9</label><element-citation publication-type="journal" id="sbref0045"><person-group person-group-type="author"><name><surname>Tsang</surname><given-names>K.W.</given-names></name><name><surname>Ho</surname><given-names>P.L.</given-names></name><name><surname>Ooi</surname><given-names>G.C.</given-names></name><name><surname>Yee</surname><given-names>W.K.</given-names></name><name><surname>Wang</surname><given-names>T.</given-names></name><name><surname>Chan-Yeung</surname><given-names>M.</given-names></name></person-group><article-title>A Cluster of Cases of Severe Acute Respiratory Syndrome in Hong Kong</article-title><source>N Eng J Med.</source><volume>348</volume><year>2003</year><fpage>1977</fpage><lpage>1985</lpage></element-citation></ref><ref id="bib0050"><label>10</label><element-citation publication-type="journal" id="sbref0050"><person-group person-group-type="author"><name><surname>Booth</surname><given-names>C.M.</given-names></name><name><surname>Matukas</surname><given-names>L.M.</given-names></name><name><surname>Tomlinson</surname><given-names>G.A.</given-names></name><name><surname>Rachlis</surname><given-names>A.R.</given-names></name><name><surname>Rose</surname><given-names>D.B.</given-names></name><name><surname>Dwosh</surname><given-names>H.A.</given-names></name></person-group><article-title>Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area</article-title><source>JAMA.</source><volume>290</volume><year>2003</year><fpage>334</fpage><pub-id pub-id-type="pmid">12865373</pub-id></element-citation></ref><ref id="bib0055"><label>11</label><element-citation publication-type="journal" id="sbref0055"><person-group person-group-type="author"><name><surname>Hsu</surname><given-names>L.Y.</given-names></name><name><surname>Lee</surname><given-names>C.C.</given-names></name><name><surname>Green</surname><given-names>J.A.</given-names></name><name><surname>Ang</surname><given-names>B.</given-names></name><name><surname>Paton</surname><given-names>N.I.</given-names></name><name><surname>Lee</surname><given-names>L.</given-names></name></person-group><article-title>Severe acute respiratory syndrome (SARS) in Singapore: clinical features of index patient and initial contacts</article-title><source>Emerg Infect Dis.</source><volume>9</volume><year>2003</year><fpage>713</fpage><lpage>717</lpage><pub-id pub-id-type="pmid">12781012</pub-id></element-citation></ref><ref id="bib0060"><label>12</label><element-citation publication-type="journal" id="sbref0060"><person-group person-group-type="author"><name><surname>Peiris</surname><given-names>J.S.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Poon</surname><given-names>L.L.</given-names></name></person-group><article-title>Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia: a prospective study</article-title><source>Lancet.</source><volume>361</volume><year>2003</year><fpage>1767</fpage><lpage>1772</lpage><pub-id pub-id-type="pmid">12781535</pub-id></element-citation></ref><ref id="bib0065"><label>13</label><element-citation publication-type="journal" id="sbref0065"><person-group person-group-type="author"><name><surname>Zhao</surname><given-names>Z.</given-names></name><name><surname>Zhang</surname><given-names>F.</given-names></name><name><surname>Xu</surname><given-names>M.</given-names></name><name><surname>Huang</surname><given-names>K.</given-names></name><name><surname>Zhong</surname><given-names>W.</given-names></name><name><surname>Cai</surname><given-names>W.</given-names></name></person-group><article-title>Description and clinical treatment of an early outbreak of severe acute respiratory syndrome (SARS) in Guangzhou, PR China</article-title><source>J Med Microbiol.</source><volume>52</volume><year>2003</year><fpage>715</fpage><lpage>720</lpage><pub-id pub-id-type="pmid">12867568</pub-id></element-citation></ref><ref id="bib0070"><label>14</label><element-citation publication-type="journal" id="sbref0070"><person-group person-group-type="author"><name><surname>Sung</surname><given-names>J.J.</given-names></name><name><surname>Wu</surname><given-names>A.</given-names></name><name><surname>Joynt</surname><given-names>G.M.</given-names></name><name><surname>Yuen</surname><given-names>K.Y.</given-names></name><name><surname>Lee</surname><given-names>N.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name></person-group><article-title>Severe acute respiratory syndrome: report of treatment and outcome after a major outbreak</article-title><source>Thorax</source><volume>59</volume><year>2004</year><fpage>414</fpage><lpage>420</lpage><pub-id pub-id-type="pmid">15115870</pub-id></element-citation></ref><ref id="bib0075"><label>15</label><element-citation publication-type="journal" id="sbref0075"><person-group person-group-type="author"><name><surname>Ooi</surname><given-names>C.G.</given-names></name><name><surname>Khong</surname><given-names>P.L.</given-names></name><name><surname>Ho</surname><given-names>J.C.</given-names></name><name><surname>Lam</surname><given-names>B.</given-names></name><name><surname>Wong</surname><given-names>W.M.</given-names></name><name><surname>Yiu</surname><given-names>W.C.</given-names></name></person-group><article-title>Severe Acute Respiratory Syndrome: Radiographic Evaluation and Clinical Outcome Measures</article-title><source>Radiology</source><volume>229</volume><year>2003</year><fpage>500</fpage><lpage>506</lpage><pub-id pub-id-type="pmid">14595150</pub-id></element-citation></ref><ref id="bib0080"><label>16</label><element-citation publication-type="journal" id="sbref0080"><person-group person-group-type="author"><name><surname>Leong</surname><given-names>H.N.</given-names></name><name><surname>Ang</surname><given-names>B.</given-names></name><name><surname>Earnest</surname><given-names>A.</given-names></name><name><surname>Teoh</surname><given-names>C.</given-names></name><name><surname>Xu</surname><given-names>W.</given-names></name><name><surname>Leo</surname><given-names>Y.S.</given-names></name></person-group><article-title>Investigational use of ribavirin in the treatment of severe acute respiratory syndrome, Singapore, 2003</article-title><source>Trop Med Int Health.</source><volume>9</volume><year>2004</year><fpage>923</fpage><lpage>927</lpage><pub-id pub-id-type="pmid">15303999</pub-id></element-citation></ref><ref id="bib0085"><label>17</label><element-citation publication-type="journal" id="sbref0085"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.S.</given-names></name><name><surname>Lai</surname><given-names>S.T.</given-names></name><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Tsui</surname><given-names>E.</given-names></name><name><surname>Tam</surname><given-names>C.Y.</given-names></name><name><surname>Wong</surname><given-names>M.M.</given-names></name></person-group><article-title>Treatment of severe acute respiratory syndrome with lopinavir/ritonavir: a multicentre retrospective matched cohort study</article-title><source>Hong Kong Med J</source><volume>9</volume><year>2003</year><fpage>399</fpage><lpage>406</lpage><pub-id pub-id-type="pmid">14660806</pub-id></element-citation></ref><ref id="bib0090"><label>18</label><element-citation publication-type="journal" id="sbref0090"><person-group person-group-type="author"><name><surname>Chu</surname><given-names>C.M.</given-names></name><name><surname>Cheng</surname><given-names>V.C.</given-names></name><name><surname>Hung</surname><given-names>I.F.</given-names></name><name><surname>Wong</surname><given-names>M.M.</given-names></name><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Chan</surname><given-names>K.S.</given-names></name></person-group><article-title>Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings</article-title><source>Thorax</source><volume>59</volume><year>2004</year><fpage>252</fpage><lpage>256</lpage><pub-id pub-id-type="pmid">14985565</pub-id></element-citation></ref><ref id="bib0095"><label>19</label><element-citation publication-type="journal" id="sbref0095"><person-group person-group-type="author"><name><surname>Yeh</surname><given-names>K.M.</given-names></name><name><surname>Chiueh</surname><given-names>T.S.</given-names></name><name><surname>Siu</surname><given-names>L.K.</given-names></name><name><surname>Lin</surname><given-names>J.C.</given-names></name><name><surname>Chan</surname><given-names>P.K.</given-names></name><name><surname>Peng</surname><given-names>M.Y.</given-names></name></person-group><article-title>Experience of using convalescent plasma for severe acute respiratory syndrome among healthcare workers in a Taiwan hospital</article-title><source>J Antimicrob Chemother.</source><volume>56</volume><year>2005</year><fpage>919</fpage><lpage>922</lpage><pub-id pub-id-type="pmid">16183666</pub-id></element-citation></ref><ref id="bib0100"><label>20</label><element-citation publication-type="journal" id="sbref0100"><person-group person-group-type="author"><name><surname>Burnouf</surname><given-names>T.</given-names></name><name><surname>Radosevich</surname><given-names>M.</given-names></name></person-group><article-title>Treatment of severe acute respiratory syndrome with convalescent plasma</article-title><source>Hong Kong Med J.</source><volume>9</volume><year>2003</year><fpage>309</fpage><comment>author reply 310</comment><pub-id pub-id-type="pmid">12904626</pub-id></element-citation></ref><ref id="bib0105"><label>21</label><element-citation publication-type="journal" id="sbref0105"><person-group person-group-type="author"><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>R.</given-names></name><name><surname>Soo</surname><given-names>Y.O.</given-names></name><name><surname>Wong</surname><given-names>W.S.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Ng</surname><given-names>M.H.</given-names></name></person-group><article-title>Use of convalescent plasma therapy in SARS patients in Hong Kong</article-title><source>Eur J Clin Microbiol Infect Dis.</source><volume>24</volume><year>2005</year><fpage>44</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15616839</pub-id></element-citation></ref><ref id="bib0110"><label>22</label><element-citation publication-type="journal" id="sbref0110"><person-group person-group-type="author"><name><surname>Soo</surname><given-names>Y.O.</given-names></name><name><surname>Cheng</surname><given-names>Y.</given-names></name><name><surname>Wong</surname><given-names>R.</given-names></name><name><surname>Hui</surname><given-names>D.S.</given-names></name><name><surname>Lee</surname><given-names>C.K.</given-names></name><name><surname>Tsang</surname><given-names>K.K.</given-names></name></person-group><article-title>Retrospective comparison of convalescent plasma with continuing high-dose methylprednisolone treatment in SARS Patients</article-title><source>Clin Microbiol Infect</source><volume>10</volume><year>2004</year><fpage>676</fpage><lpage>678</lpage><pub-id pub-id-type="pmid">15214887</pub-id></element-citation></ref><ref id="bib0115"><label>23</label><element-citation publication-type="journal" id="sbref0115"><person-group person-group-type="author"><name><surname>Loutfy</surname><given-names>M.R.</given-names></name><name><surname>Blatt</surname><given-names>L.M.</given-names></name><name><surname>Siminovitch</surname><given-names>K.A.</given-names></name><name><surname>Ward</surname><given-names>S.</given-names></name><name><surname>Wolff</surname><given-names>B.</given-names></name><name><surname>Lho</surname><given-names>H.</given-names></name></person-group><article-title>Interferon alfacon-1 plus corticosteroids in severe acute respiratory syndrome: a preliminary study</article-title><source>JAMA.</source><volume>290</volume><year>2003</year><fpage>3222</fpage><lpage>3228</lpage><pub-id pub-id-type="pmid">14693875</pub-id></element-citation></ref><ref id="bib0120"><label>24</label><element-citation publication-type="journal" id="sbref0120"><person-group person-group-type="author"><name><surname>Chan</surname><given-names>K.H.</given-names></name><name><surname>Chan</surname><given-names>J.F.</given-names></name><name><surname>Tse</surname><given-names>H.</given-names></name><name><surname>Chen</surname><given-names>H.</given-names></name><name><surname>Lau</surname><given-names>C.C.</given-names></name><name><surname>Cai</surname><given-names>J.P.</given-names></name></person-group><article-title>Cross-reactive antibodies in convalescent SARS patients’ sera against the emerging novel human coronavirus EMC (2012) by both immunofluorescent and neutralizing antibody tests</article-title><source>J Infect.</source><volume>67</volume><year>2013</year><fpage>130</fpage><lpage>140</lpage><pub-id pub-id-type="pmid">23583636</pub-id></element-citation></ref><ref id="bib0125"><label>25</label><mixed-citation publication-type="other" id="oref0125">ISARIC, International Severe Acute Respiratory & Emerging Infection Consortium. Clinical Decision Making Tool for Treatment of MERS-CoV v.1.0, 18 June, 2013. Available at: <ext-link ext-link-type="uri" xlink:href="http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416" id="intr0020">http://www.hpa.org.uk/webc/HPAwebFile/HPAweb_C/1317139281416</ext-link> last accessed July 26, 2013</mixed-citation></ref><ref id="bib0130"><label>26</label><element-citation publication-type="journal" id="sbref0130"><person-group person-group-type="author"><name><surname>Raj</surname><given-names>V.S.</given-names></name><name><surname>Mou</surname><given-names>H.</given-names></name></person-group><article-title>Dipeptidyl peptidase 4 is a functional receptor for the emerging human coronavirus-EMC</article-title><source>Nature.</source><volume>495</volume><year>2013</year><fpage>251</fpage><lpage>254</lpage><pub-id pub-id-type="pmid">23486063</pub-id></element-citation></ref></ref-list><ack id="ack0005"><title>Acknowledgements</title><p>The authors (HAM, MK, and JAT) wish to acknowledge the use of Saudi Aramco Medical Services Organization (SAMSO) facilities for the data and study, which resulted in this paper. Opinions expressed in this article are those of the authors and not necessarily of SAMSO. Professor Zumla acknowledges support from the University College London Hospitals NHS Foundation Trust, the National Institute of Health UCLH Biomedical Research Centre, the EDCTP and the EC-FW7. Authors thank Dr. Paul Anantharajah Tambyah from National University of Singapore's Department of Medicine for his critical review of the manuscript.</p><p><italic>Financial support:</italic> None</p></ack></back></pmc></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Pmc/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000D49 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd -nk 000D49 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Pmc
|étape= Corpus
|type= RBID
|clé= PMC:7110699
|texte= Therapeutic Options for Middle East Respiratory Syndrome Coronavirus (MERS-CoV) – possible lessons from a systematic review of SARS-CoV therapy
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Pmc/Corpus/RBID.i -Sk "pubmed:23993766" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Pmc/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a MersV1
| This area was generated with Dilib version V0.6.33. |  |